Abstract:Achieving high-efficiency tumor targeting after systemic delivery is a considerable challenge facing oncolytic gene therapists. Efficient retargeting should be combined with efforts to improve in vivo safety, reduce hepatotoxicity, minimize off-target interactions, and improve antitumoral potency and efficacy. We previously described the successful retargeting of adenovirus serotype 5 (Ad5) to α(v)β(6), an integrin that is highly overexpressed in numerous human carcinomas. In this study, we have further modified this construct by introducing mutations that ablate coxsackievirus-adenovirus receptor (CAR) binding and putative interactions with factor IX (FIX)/C4b-binding protein (C4BP). We have found that the resulting vector, Ad5-477dlTAYT(A20), displays a desirable in vivo safety profile. This vector does not agglutinate human erythrocytes, fails to cause thrombocytopenia after intravenous delivery, has limited induction of proinflammatory cytokines, and results in low-level toxicity (aspartate aminotransferase/alanine aminotransferase) when compared with Ad5-EGFP(WT). Furthermore, it has reduced accumulation in Kupffer cells (1 hr) and limited hepatocyte transduction at later time points (24 and 96 hr). The parental vector, Ad5-EGFP(A20), also displayed many of these desirable properties. As a result of the improved safety profile of both A20-modified vectors, we escalated the dose from 2×10(10) to 4×10(10) viral particles in an antitumoral efficacy study. We observed improvements in reducing percent tumor growth at early time points (96 hr) when compared with Ad5-EGFP(WT), although increasing the dose did not affect the therapeutic outcome beneficially. On completion of the experiment, we detected increased E1A staining in the tumors of all A20-treated groups and we determined that E1A expression was localized largely within α(v)β(6)(+) tumor cells. However, in spite of apparently efficient tumor transduction, this did not result in enhanced antitumoral efficacy as the virus failed to disseminate effectively throughout the tumor mass, presumably due to physical intratumoral restrictions. This highlights a remaining challenge that needs to be overcome before such vectors can be developed for future cancer gene therapy applications.

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver

Site-Specific PEGylated Adeno-Associated Viruses with Increased Serum Stability and Reduced Immunogenicity.

Pegylated Adenovirus Vectors Containing Rgd Peptides on the Tip of Peg Show High Transduction Efficiency and Antibody Evasion Ability

Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.

Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction

Neutralizing Antibody Evasion Ability Of Adenovirus Vector Induced By The Bioconjugation Of Methoxypolyethylene Glycol Succinimidyl Propionate (Mpeg-Spa)

Optimization and Internalization Mechanisms of PEGylated Adenovirus Vector with Targeting Peptide for Cancer Gene Therapy

Functional Characterization of a PEI-CyD-FA-coated Adenovirus As Delivery Vector for Gene Therapy.

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

Activation of TLR9 by incorporated pDNA within PEG-coated lipoplex enhances anti-PEG IgM production

The use of PEGylated poly [2-(N,N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses.

Polyethylene glycol modified polyethylenimine for improved CNS gene transfer: effects of PEGylation extent

Encapsulating Polyethyleneimine-DNA Nanoplexes into PEGylated Biodegradable Microparticles Increases Transgene Expression In Vitro and Reduces Inflammatory Responses In Vivo

Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy

Macrophage Inhibitor Clodronate Enhances Liver Transduction of Lentiviral but Not Adeno-Associated Viral Vectors or mRNA Lipid Nanoparticles in Neonatal and Juvenile Mice

Considerations for Use of Recombinant Adenoviral Vectors: Dose Effect on Hepatic Cytochromes P450

Repeated Systemic Dosing of Adeno-Associated Virus Vectors in Immunocompetent Mice After Blockade of T Cell Costimulatory Pathways

RGD Modification Improves the Transfection Efficiency of Adenovirus Vectors Carrying Double Objective Genes

Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5

Linear and multivalent PEGylation of the tobacco mosaic virus and the effects on its biological properties

Terminal Modification on Mpeg-Dendritic Poly-(L)-Lysine Cationic Diblock Copolymer for Efficient Gene Delivery